Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05035836 | A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC) | PHASE2 | RECRUITING | 20 | — | — | Nov 16, 2021 | Dec 29, 2028 | Jun 5, 2026 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Zanidatamab | EXPERIMENTAL | zanidatamab by vein every 2 weeks (+/- 3 days) for up to 6 doses (3 study cycles |
| Name | Type | Description |
|---|---|---|
| Zanidatamab | DRUG | Given IV |
| Letrozole | DRUG | Given by PO |
| Tamoxifen | DRUG | Given by PO |
Inclusion Criteria: 1. Ability to give written informed consent 2. Age \> 18 years at time of study entry. 3. Patient would be willing to undergo surgery is appropriate for surgery 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (Appendix 1). 5. Tumor size \> 1 cm to ≤ 3 c...